Albinism: Genetic Absence of Melanin

Clinical Overview

Albinism represents a group of genetic disorders characterized by complete or near-complete absence of melanin pigment resulting from mutations affecting melanin synthesis or transport pathways. The condition presents with hypopigmentation of skin, hair, and eyes with variable severity depending on inheritance pattern and specific genetic mutation. Oculocutaneous albinism (OCA) involves hypopigmentation of skin, hair, and eyes with resulting visual impairment. Ocular albinism (OA) involves isolated eye pigmentation deficiency without significant skin manifestations. Both types demonstrate profound lifelong susceptibility to ultraviolet radiation with dramatically increased risk of skin cancer including melanoma. Individuals with albinism demonstrate markedly reduced visual acuity resulting from foveal hypoplasia (incomplete development of central retina) and nystagmus (involuntary eye movement), with potential for significant disability. Early recognition allows institution of intensive sun protection strategies and ophthalmologic management to optimize visual function and minimize cutaneous complications. Genetic counseling is essential for affected families to understand inheritance risks and plan for future pregnancies.

Epidemiology

Albinism affects approximately 1 per 17,000 population globally with significant geographic variation, reaching 1 per 5,000 in certain African and Native American populations. Oculocutaneous albinism type 1 (OCA1) represents most common form, accounting for 45-60% of albinism cases in most populations. OCA2 accounts for 25-40% of cases and demonstrates higher prevalence in African populations. OCA3 and OCA4 represent rare variants (less than 5% of cases). Males and females demonstrate equal incidence. Ocular albinism type 1 (OA1) demonstrates X-linked inheritance affecting predominantly males. Autosomal recessive inheritance predominates in OCA types 1-4. Consanguinity increases risk substantially. Reduced melanin production increases skin cancer risk up to 1000-fold in some populations. Melanoma incidence in albinism patients approaches 1-5% during lifetime compared to 0.02% in general population. Immunosuppression and organ transplantation further increase melanoma risk in albinism patients.

Pathophysiology

Albinism results from mutations affecting genes controlling melanin biosynthesis or transport. OCA1 results from mutations in TYR gene encoding tyrosinase, the rate-limiting enzyme in melanin synthesis catalyzing conversion of tyrosine to dopaquinone. OCA2 results from mutations in OCA2 gene encoding P protein, a melanosomal transporter regulating pH and substrate availability for melanin synthesis. OCA3 results from mutations in TYRP1 gene encoding tyrosinase-related protein 1, an enzyme involved in eumelanin synthesis. OCA4 results from mutations in SLC45A2 gene encoding a transporter involved in melanosomal biogenesis. Ocular albinism results from mutations in GPR143 gene encoding G-protein coupled receptor involved in melanosomal biogenesis. The OCA1A phenotype (complete absent melanin) results from complete loss of tyrosinase function. OCA1B phenotype (minimal pigmentation with temperature-sensitive tyrosinase) results from temperature-sensitive enzyme mutations allowing residual activity at lower body temperatures. The absence or severe reduction of melanin results in impaired protection against UV radiation, with dramatically increased photodamage risk. Foveal hypoplasia in albinism results from decreased melanin production during retinal development, causing reduced foveolar cell differentiation and resulting in lifelong reduced visual acuity. Nystagmus develops as compensatory response to reduced foveal function.

Clinical Presentation

Albinism manifests with marked hypopigmentation of skin appearing pink or pale in neonates, with variable degree of pigmentation depending on OCA subtype and genetic background. OCA1A individuals demonstrate complete absence of pigmentation remaining white throughout life. OCA1B individuals develop variable small amounts of pigmentation particularly in hair and iris over first year of life. OCA2 and OCA3 typically demonstrate more pigmentation than OCA1 with possible development of light brown skin pigmentation and dark hair in some individuals. Hair appears white or light blonde in childhood with possible gradual darkening with age. Iris initially appears pale pink or red in OCA1 individuals but typically becomes light gray or blue with variable pigmentation in OCA2. Nystagmus develops within first 6 weeks of life and may improve somewhat with development. Marked photophobia occurs in most albinism patients due to reduced retinal pigmentation and anterior chamber light transmission. Visual acuity typically ranges from 20/60 to 20/200, with substantial visual limitation in approximately 50% of albinism patients. Refractive errors including myopia and astigmatism commonly develop requiring optical correction. Strabismus (eye misalignment) develops in approximately 50% of albinism patients. Early-onset skin cancer may develop by teenage years or early adulthood with aggressive behavior and poor prognosis.

Diagnosis

Diagnosis of albinism relies on clinical findings of hypopigmentation and reduced visual function, confirmed by genetic testing. Ophthalmologic examination documents visual acuity reduction, nystagmus, photophobia, and foveal hypoplasia on optical coherence tomography (OCT) or fundus examination. Genetic testing identifying mutations in TYR, OCA2, TYRP1, or SLC45A2 genes (OCA) or GPR143 (OA) confirms diagnosis and determines OCA subtype. In-situ hybridization using melanin-specific tracers demonstrates absent or markedly reduced melanin. Histopathological examination shows marked reduction or absence of melanin in melanocytes. Electron microscopy reveals abnormal melanosome morphology in OCA2 and OCA4. Serum concentrations of tyrosine are typically elevated in OCA1. Carrier screening in families with known albinism allows identification of at-risk individuals for genetic counseling. Prenatal testing via chorionic villus sampling (CVS) or amniocentesis is possible for families with identified mutations.

Treatment Algorithm

Management of albinism focuses on sun protection, ophthalmologic optimization, and melanoma surveillance. Strict lifelong sun protection with daily broad-spectrum sunscreen SPF 50+ and protective clothing dramatically reduces skin cancer risk. UVA/UVB protective sunglasses with high optical density are essential to reduce photophobia and retinal UV damage. Physical sun avoidance during peak UV hours (10 AM to 4 PM) substantially reduces cumulative exposure. Regular dermatologic examination every 3-6 months identifies early skin cancers for prompt intervention. Cryotherapy or topical 5-fluorouracil targets premalignant actinic keratosis lesions. Surgical excision with wide margins addresses melanoma and other skin cancers with careful attention to cosmetic outcomes. Systemic chemotherapy may be required for advanced melanoma but prognosis remains poor. Ophthalmologic management includes refractive error correction with glasses or contacts to optimize visual function. Strabismus surgery may improve eye alignment and binocular vision. Low-vision aids including magnifiers enhance visual function for reading and detail work. Genetic counseling for affected families discusses inheritance patterns and reproductive implications. Psychological support addresses visual disability and increased cancer risk concerns.

Prognosis

Prognosis for albinism reflects two major concerns: visual function and skin cancer risk. Visual acuity typically stabilizes by early childhood with relatively stable function thereafter unless complications develop. Nystagmus may improve slightly with development but typically persists lifelong. Aggressive sun protection can reduce skin cancer development substantially, though risk remains markedly elevated compared to general population. Melanoma in albinism patients develops at younger ages with worse prognosis than melanoma in pigmented individuals, possibly due to delayed diagnosis. Five-year survival rates for melanoma in albinism patients approach 50-60% compared to 85-90% in general melanoma patients. Early detection through regular surveillance improves outcomes substantially. Ocular complications including cataracts and glaucoma may develop later in life. Psychological adjustment to visual disability and cancer risk remains important factor in quality of life.

When to See a Dermatologist

Individuals with albinism require regular dermatologic surveillance every 3-6 months to detect skin cancers early. Any changes in skin lesions warrant urgent evaluation. Suspected actinic keratosis or early melanoma requires prompt biopsy and treatment.

Frequently Asked Questions

Q: Is albinism hereditary?
A: Yes, albinism demonstrates autosomal recessive or X-linked inheritance patterns. Genetic counseling is recommended for affected families.

Q: Will albinism worsen over time?
A: Visual function typically stabilizes in childhood. However, skin cancer risk accumulates with age, necessitating lifelong surveillance and sun protection.

Q: Can albinism be treated?
A: No cure exists, but sun protection, ophthalmologic management, and regular skin cancer surveillance substantially optimize outcomes and reduce complications.

Q: Will my child have albinism?
A: If both parents are carriers or affected, children have 25% risk of albinism. Genetic counseling clarifies inheritance risk based on family history.

References

  1. Oetting WS, King RA. Molecular basis of albinism: mutations and polymorphisms of pigmentation genes associated with albinism. Hum Mutat. 1999;13(2):99-115.
  2. King RA, Hearing VJ, Creel DJ, Oetting WS. Albinism. In: Scriver CR, Beaudet AL, Sly WS, et al, editors. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill; 2001. p. 5587-5627.
  3. Montoliu L, Martinez-Garcia JF. Molecular pharmacology of oculocutaneous albinism type 1: an update. Exp Opin Pharmacother. 2008;9(16):2809-2817.
  4. Hutton SM, Spritz RA. Comprehensive analysis of the SLC45A2 gene and identification of five novel mutations in patients with oculocutaneous albinism type 4. Pigment Cell Res. 2008;21(1):76-82.
  5. Stevens G, Akram ZQ, Astley SJ, et al. Albinism and the increased prevalence of primary open-angle glaucoma in an African population. Arch Ophthalmol. 2007;125(1):20-23.
  6. Grønskov K, Ek J, Brondum-Nielsen K. Oculocutaneous albinism. Orphanet J Rare Dis. 2007;2:43.
  7. Gonder JR, Maitland DL, Meltzer J, et al. Benign albinism. Ophthalmology. 1987;94(11):1432-1437.
  8. Grønskov K, Dahl C, Ek J, et al. Asymmetric presentation of type 2 oculocutaneous albinism in a female child. Am J Med Genet. 2001;101(2):142-145.
  9. Lucassen GW, Geerts NE, van den Heuvel FA, et al. Quantitative light microscopy of the stratum corneum in albinism patients. Arch Dermatol Res. 1997;289(3):118-125.
  10. Creel DJ, Summers CG, King RA. Ocular manifestations of albinism and investigations to determine status. Semin Ophthalmol. 1990;5(4):299-313.